Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Director Martha J. Demski Sells 2,000 Shares

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Director Martha J. Demski sold 2,000 shares of Adamas Pharmaceuticals stock in a transaction that occurred on Monday, June 7th. The stock was sold at an average price of $5.17, for a total transaction of $10,340.00. Following the completion of the sale, the director now directly owns 8,000 shares of the company’s stock, valued at $41,360. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of ADMS opened at $5.15 on Friday. The firm has a market cap of $213.04 million, a price-to-earnings ratio of -2.88 and a beta of 2.71. The company has a fifty day moving average of $5.18. Adamas Pharmaceuticals, Inc. has a fifty-two week low of $2.43 and a fifty-two week high of $9.15. The company has a debt-to-equity ratio of 21.25, a quick ratio of 5.16 and a current ratio of 5.42.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Sunday, May 9th. The specialty pharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.15. The company had revenue of $19.31 million during the quarter, compared to analyst estimates of $19.59 million. Equities research analysts anticipate that Adamas Pharmaceuticals, Inc. will post -1.1 EPS for the current year.

Several analysts have commented on the stock. HC Wainwright lifted their target price on shares of Adamas Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Monday. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research note on Monday, May 17th. Finally, SVB Leerink reaffirmed a “buy” rating and issued a $6.00 target price on shares of Adamas Pharmaceuticals in a research note on Thursday, May 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $9.06.

Institutional investors and hedge funds have recently made changes to their positions in the business. Altium Capital Management LP acquired a new position in shares of Adamas Pharmaceuticals in the 1st quarter valued at $2,160,000. Morgan Stanley lifted its holdings in shares of Adamas Pharmaceuticals by 270.0% during the 4th quarter. Morgan Stanley now owns 1,107,225 shares of the specialty pharmaceutical company’s stock valued at $4,794,000 after acquiring an additional 807,951 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Adamas Pharmaceuticals by 9.1% during the 4th quarter. Renaissance Technologies LLC now owns 898,584 shares of the specialty pharmaceutical company’s stock valued at $3,891,000 after acquiring an additional 74,580 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 0.8% during the 4th quarter. BlackRock Inc. now owns 534,913 shares of the specialty pharmaceutical company’s stock valued at $2,316,000 after acquiring an additional 3,994 shares in the last quarter. Finally, Silverarc Capital Management LLC acquired a new position in shares of Adamas Pharmaceuticals during the 4th quarter valued at $1,909,000. Institutional investors own 69.82% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.

Featured Story: Intrinsic Value

Insider Buying and Selling by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.